Literature DB >> 19130116

Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience.

Chan Kyo Kim1, Byung Kwan Park, Won Park, Sam Soo Kim.   

Abstract

The purpose of this study was to retrospectively assess the diagnostic performance of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced imaging (DCEI) at 3T in predicting locally recurrent prostate cancer after radiation therapy. Twenty-four patients with a rising prostate-specific antigen level after treatment with radiation therapy underwent prostate MR imaging at 3T, followed by transrectal ultrasound-guided biopsy. MRI findings and biopsy results were correlated in six prostate sectors of both peripheral zones. Two radiologists in consensus reviewed the MR images and rated the likelihood of recurrent cancer on a 5-point scale. Out of the 144 prostate sectors, 37 (26%) sectors were positive for cancer in ten patients. For predicting locally recurrent cancer, the sensitivity and specificity of DWI, DCEI, and combined DCEI and DWI were higher than those for T2-weighted imaging (T2WI). The accuracy of DWI, DCEI and combined DCEI and DWI was greater than that of T2WI. A significantly greater Az was determined for combined DCEI and DWI (Az = 0.863, P < 0.05) as compared with T2WI, DCEI, and DWI. For predicting locally recurrent prostate cancer after radiation therapy, our preliminary results suggest that the use of either DWI or DCEI is superior to the use of T2WI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19130116     DOI: 10.1007/s00261-008-9495-2

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  27 in total

Review 1.  Diffusion weighted imaging in prostate cancer.

Authors:  Cher Heng Tan; Jihong Wang; Vikas Kundra
Journal:  Eur Radiol       Date:  2010-10-09       Impact factor: 5.315

2.  Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging.

Authors:  Kolja M Thierfelder; Michael K Scherr; Mike Notohamiprodjo; Jakob Weiß; Olaf Dietrich; Ullrich G Mueller-Lisse; Josef Pfeuffer; Konstantin Nikolaou; Daniel Theisen
Journal:  Eur Radiol       Date:  2014-08-27       Impact factor: 5.315

3.  Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation.

Authors:  Ely R Felker; Steven S Raman; David S K Lu; Mitch Tuttle; Daniel J Margolis; Fuad F ElKhoury; James Sayre; Leonard S Marks
Journal:  AJR Am J Roentgenol       Date:  2019-07-30       Impact factor: 3.959

4.  Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images.

Authors:  M Abd-Alazeez; N Ramachandran; N Dikaios; H U Ahmed; M Emberton; A Kirkham; M Arya; S Taylor; S Halligan; S Punwani
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-03       Impact factor: 5.554

Review 5.  Prostate MR Imaging for Posttreatment Evaluation and Recurrence.

Authors:  Sonia Gaur; Baris Turkbey
Journal:  Radiol Clin North Am       Date:  2017-11-27       Impact factor: 2.303

6.  [Multiparametric prostate MRI for follow-up monitoring after radiation therapy].

Authors:  A M Weidner; D J Dinter; M Bohrer; M Sertdemir; D Hausmann; F Wenz; S O Schoenberg
Journal:  Radiologe       Date:  2012-03       Impact factor: 0.635

Review 7.  Roundtable: arguments in support of using multi-parametric prostate MRI protocol.

Authors:  Sirisin Kamsut; Kimberly Reid; Nelly Tan
Journal:  Abdom Radiol (NY)       Date:  2020-12

Review 8.  Clinical applications for diffusion magnetic resonance imaging in radiotherapy.

Authors:  Christina Tsien; Yue Cao; Thomas Chenevert
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

9.  [Prostate cancer].

Authors:  T Franiel; N Eckardt; M Waginger; M Horstmann
Journal:  Radiologe       Date:  2014-05       Impact factor: 0.635

Review 10.  Multidisciplinary functional MR imaging for prostate cancer.

Authors:  Jeong Kon Kim; Yun-Jin Jang; Gyunggoo Cho
Journal:  Korean J Radiol       Date:  2009 Nov-Dec       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.